Seedlabs

PCSK9i First-Event Benefit Card

A simple card helping doctors and patients decide if a cholesterol injection is right for someone who has never had a heart attack.

A point-of-care card that translates the new first-event prevention trial into plain-language absolute numbers, so clinicians and asymptomatic patients can decide together whether to start a twice-monthly cholesterol injection.

MedicineLipoproteins and Cardiovascular Health
Metabolism and Genetic DisordersPoint-of-care shared decision-making in primary care, endocrinology, and preventive cardiology

Concept

A point-of-care shared-decision card for primary care, endocrinology, and preventive cardiology: for an individual patient with atherosclerosis or diabetes, no prior heart attack or stroke, and LDL ≥90 mg/dL, the card renders the trial's absolute numbers in plain language — roughly 2 fewer deaths from coronary heart disease, heart attacks, or ischemic strokes, and about 3 fewer events including artery-opening procedures, per 100 patients treated over 5 years — alongside what treatment asks of the patient (a self-injection every 2 weeks, indefinitely) and the clean safety result. The output is a one-page start-now-or-defer conversation aid, not a mandate; the wedge is making honest absolute-benefit framing the centerpiece of a first-event prevention decision.

Why now

[0] reports directly usable absolute numbers: 5-year Kaplan-Meier event rates of 6.2% vs 8.0% (3-point MACE) and 13.4% vs 16.2% (4-point MACE) for evolocumab vs placebo, with no evidence of a between-group difference in safety events. In secondary prevention, intensifying therapy is routine; in this new event-free population, an asymptomatic person is weighing a biweekly injectable against a 1.8–2.8 percentage-point absolute risk reduction over roughly 5 years, so the decision — and long-term adherence — hinges on absolute-benefit framing anchored to the trial's own 5-year estimates.

Written by GLM · 12 Oct 2026

AI assessment

Backed by 1 paper88

A low-complexity clinical decision aid that translates high-impact trial data into patient-facing absolute risk numbers to drive adoption of PCSK9 inhibitors in a new patient population.

Evidence strength
5/5
The idea directly utilizes the specific 5-year Kaplan-Meier event rates (3-point and 4-point MACE) provided in the full text of the evolocumab trial.
Market pull
4/5
There is strong urgency for clinicians to communicate the value proposition of expensive injectables to asymptomatic patients to justify the cost and burden.
Novelty & moat
3/5
While shared-decision aids exist, this is a specific application for a newly proven population, though it follows a similar pattern to the 'Incretin Switch Card' in the catalog.
Feasibility
5/5
The product is a simple information design task requiring no software development or clinical trials, making it immediately deployable.
Wedge clarity
5/5
The wedge is highly specific: using absolute-benefit framing to solve the 'asymptomatic patient' hesitation for a specific drug class.
Simplicity / focus
5/5
The idea is focused on a single, sharp product (a decision card) rather than an over-scoped platform.

Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Cleveland Clinicorganization

    Operates a large preventive-cardiology program whose clinicians face exactly this start-or-defer conversation with asymptomatic, high-LDL patients.

  • American Diabetes Associationorganization

    The trial enrolled diabetes patients without prior events; a plain-language benefit card supports its patient-education mission and Standards of Care updates for this group.

  • American Heart Associationorganization

    Patient-facing education on cholesterol treatment decisions is core to its mission; the card's absolute-number framing fits its shared-decision resources.

  • Healthwiseorganization

    Produces patient-education content embedded in major EHRs; a trial-anchored decision card is directly licensable, evidence-current content.

Research it builds on

  1. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
    Erin Ann Bohula, Nicholas Marston, Ajay K. Bhatia et al. · 2025 · 112 citations
    All ideas from this paper →
Leave feedback
feasibility